Coexistence effect of hypertension and angiotensin II on the risk of coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China

References

• Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr. 2001;10:76–80.
   PubMed Web of Science ®Google Scholar
• Kelly BB, Narula J, Fuster V. Recognizing global burden of cardiovascular disease and related chronic diseases. Mt Sinai J Med. 2012;79:632–640.
   PubMedGoogle Scholar
• Institute of Medicine Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing C. The National Academies collection: Reports funded by National Institutes of Health. In: Fuster V, Kelly BB, editors. Promoting Cardiovascular health in the developing world: A critical challenge to achieve global health. Washington (DC): National Academies Press; 2010.
   Google Scholar
• Fuster V, Kelly BB, Vedanthan R. Promoting global cardiovascular health: moving forward. Circulation. 2011;123:1671–1678.
   PubMed Web of Science ®Google Scholar
• Deaton C, Froelicher ES, Wu LH, et al. The global burden of cardiovascular disease. J Cardiovasc Nurs. 2011;26:S5.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD, editors. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. GBD Series. Vol. I. Cambridge (MA): Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.
   Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223.
   PubMed Web of Science ®Google Scholar
• Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25:73–79.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen G, Tian H, et al. Prevalence of hypertension in China: a cross-sectional study. PLoS One. 2013;8:e65938.
   PubMed Web of Science ®Google Scholar
• van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–2097.
   PubMed Web of Science ®Google Scholar
• Ellis KL, Palmer BR, Frampton CM, et al. Genetic variation in the renin–angiotensin–aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease. J Hum Hypertens. 2013;27:237–244.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Van VL, Akkerhuis M, et al. Impact of renin–angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis. Int J Cardiol. 2015;181:425–429.
   PubMed Web of Science ®Google Scholar
• Yu Y, Xue BJ, Wei SG, et al. Activation of central PPAR-γ attenuates angiotensin II-induced hypertension. Hypertension. 2015;66:403–411.
   PubMed Web of Science ®Google Scholar
• Herichova I, Szantoova K. Renin–angiotensin system: upgrade of recent knowledge and perspectives. Endo. 2013;47:39–52.
   Google Scholar
• Zhang Y, Thompson AM, Tong W, et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China. J Hypertens. 2010;28(1):35–40. DOI:10.1097/HJH.0b013e3283324650
   Google Scholar
• Li H, Tan X, Tong W, et al. Comparison of cardiovascular risk factors between prehypertension and hypertension in a Mongolian population, Inner Mongolia, China. Circ J. 2008;72:1666–1673.
   PubMed Web of Science ®Google Scholar
• Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88:2460–2470.
   PubMed Web of Science ®Google Scholar
• Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–475.
   PubMed Web of Science ®Google Scholar
• Sitzmann FC, Eschler P. [Enzymatic determination of blood glucose with a modified hexokinase method]. Med Klin. 1970;65:1178.
   PubMedGoogle Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Kuulasmaa K. WHO MONICA project: assessing CHD mortality and morbidity. Int J Epidemiol. 1989;18:38–45.
   PubMed Web of Science ®Google Scholar
• He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–1134. DOI:10.1056/NEJMsa050467.
   PubMed Web of Science ®Google Scholar
• Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441.
   PubMed Web of Science ®Google Scholar
• Weiss D, Taylor WR. Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II. Hypertension. 2008;51:218–224.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ, et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
   PubMed Web of Science ®Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535.
   PubMed Web of Science ®Google Scholar
• Jia EZ, Chen ZH, An FH, et al. Relationship of renin–angiotensin–aldosterone system polymorphisms and phenotypes to mortality in Chinese coronary atherosclerosis patients. Sci Rep. 2014;4:4600.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;326:669–677.
   Web of Science ®Google Scholar
• Effects BPD. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. New Engl J Med. 1992;327:685–691.
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–1378.
   PubMed Web of Science ®Google Scholar
• Thavarajah S, Mansoor GA. Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects? Curr Hypertens Rep. 2002;4:290–297.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Coppo M, Bandinelli M, Berni A, et al. Ang II upregulation of the T-Lymphocyte Renin–angiotensin system is amplified by low-grade inflammation in human hypertension. Am J Hypertens. 2011;24:716.
   PubMed Web of Science ®Google Scholar
• Gonzalez Villalobos RA, Satou RN, Semprun Prieto LC, et al. Intrarenal mouse renin–angiotensin system during ANG II-induced hypertension and ACE inhibition. Am J Physiol Renal Physiol. 2010;298:F150.
   PubMed Web of Science ®Google Scholar
• Porter JP. Chronic intracerebroventricular infusion of angiotensin II increases brain AT1 receptor expression in young rats. Brain Res Dev Brain Res. 1999;112:293.
   PubMedGoogle Scholar
• Wei SG, Yu Y, Zhang ZH, et al. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol. 2009;296:H1425.
   Web of Science ®Google Scholar
• Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
   PubMed Web of Science ®Google Scholar
• Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part II: AT(1) receptor regulation. Circulation. 2002;105:530–536.
   PubMed Web of Science ®Google Scholar
• Wassmann S, Czech T, Van EM, et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation. 2004;110:3062.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Imanishi T, Akasaka T. Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model. Hypertens Res. 2006;29:449.
   PubMed Web of Science ®Google Scholar
• Doran DE, Weiss D, Zhang Y, et al. Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis. 2007;195:39–47.
   PubMed Web of Science ®Google Scholar
• Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice. J Clin Invest. 2000;105:1605–1612.
   PubMed Web of Science ®Google Scholar
• THOPES Investigators. Effects of an angiotensin-coverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patient. New Engl J Med. 2000;342:145–153.
   PubMed Web of Science ®Google Scholar